The assumption that genes encoding tyrosine kinase receptors could play a role in human cancers has been confirmed by the identification of oncogenic mutations in the kinase domain of RET and KIT. Recently, homologous residues were found mutated in MET, in papillary renal carcinomas (PRCs). The link coupling these genetic lesions to cellular transformation is still unclear. MET PRC mutations result in increased kinase activity and-in some instances, i.e., M1250T substitution-in changes in substrate specificity. A direct correlation occurs between the transforming potential of MET PRC mutants and their ability to constitutively associate with signal transducers through two phosphorylated tyrosines (Y 1349 VHVNATY 1356 VNV) located in the receptor tail. Substitution of these ''docking tyrosines'' with phenylalanines leaves unaffected the altered properties of the kinase but abrogates transformation and invasiveness in vitro. Uncoupling the receptor from signal transducers with a tyrosine-phosphorylated peptide derivative (Y p VNV) inhibits invasive growth induced by MET PRC mutants. These data indicate that constitutive receptor coupling to downstream signal transducers is a key mechanism in neoplastic transformation driven by mutated MET and suggest a therapeutic strategy to target neoplastic diseases associated with this oncogene.
Germ-line missense mutations involving the RET protooncogene are found in patients affected by multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) or familial medullary thyroid carcinomas (1, 2) . Somatic mutations of KIT are found in mastocytomas and in gastrointestinal tumors (3) (4) (5) . Germ-line and sporadic mutations of MET have been recently described in papillary renal carcinomas (PRCs) (6, 7) . Interestingly, the mutations found within the kinase domain of RET (M918T) and KIT (D816V) are located in codons that are homologous to those mutated in MET (M1250T, D1228N, and D1228H) ‡ . These mutations invariably result in up-regulation of the tyrosine kinase activity of the encoded receptors (9) (10) (11) (12) . The molecular mechanism coupling this biochemical alteration to the oncogenic properties of the mutated proteins is unclear. In RET and KIT, mutations of specific residues located in the kinase domain alter substrate specificity, thus affecting signaling fidelity (9, (13) (14) (15) . Mutated RET and KIT receptors also display a different array of autophosphorylation sites, an altered ability to interact with signal transducers, and modified down-regulation mechanisms (10, 13, (16) (17) (18) (19) . It is still unclear which of these alterations is relevant for the oncogenic properties of the mutants.
MET receptor variants have been identified harboring the mutations previously found in the kinase domain of RET and
KIT. This provides the opportunity to elucidate the molecular mechanisms responsible for neoplastic transformation driven by activated tyrosine kinase receptors.
The MET receptor binds at high affinity to the hepatocyte growth factor͞scatter factor (20, 21) . Signaling via this ligandreceptor pair promotes a unique biological program leading to ''invasive growth.'' This phenotype results from the integration of distinct biological activities including cell proliferation, motility, extracellular matrix invasion, and protection from apoptosis (22) . MET-mediated invasive growth requires concomitant activation of multiple signaling pathways (23) . This is achieved by receptor coupling to a number of effectors, among which are the Grb2͞SOS complex, the p85 regulatory subunit of phosphatidylinositol 3-kinase, Stat-3, and the multiadaptor protein Gab1 (24) (25) (26) (27) (28) (29) (30) . The interaction occurs on phosphorylation of a unique docking site containing the tandemly repeated sequence Y 1349 VHVNATY 1356 VNV (26) .
METHODS
Reagents, Peptides, Antibodies, and Cell Culture. All reagents used were from Fluka and Sigma. Reagents for SDS͞ PAGE were from Bio-Rad. N-acetylated and C-amidated synthetic peptides Y p VNVY p and FVNV were synthesized by fluorenylmethoxycarbonyl (Fmoc) chemistry and purified by HPLC (Ͼ99%). For in vivo electroporation, the phosphate group was replaced by the nonhydrolyzable methylenphosphonate group (30) . The peptide containing the MET docking sites fused to an antennapedia sequence RQIKIWFQNRRM-KWKKIGEHY 1349 VHVNATY 1356 VNVKCVA, the optimal peptide substrates for the epidermal growth factor receptor (AEEEEYFELVAKKKK), the Abl cytosolic kinase (EAIY-AAPFAKKK), or the Src kinase (AEEEIYGEFEAKKK) were obtained from Genosys (U.K.). Anti-phosphotyrosine, anti-p130Cas, and anti-Gab1 antibodies were purchased from Upstate Biotechnology. Anti-MET antibodies were obtained as described (34) . COS7 and BOSC-23 were from the American Type Culture Collection. NIH 3T3 cells (a kind gift of J. H. Pierce, National Cancer Institute, Bethesda, MD) were found to produce 10-30 scatter units͞ml. Cultures of mammalian cells were maintained in DMEM supplemented with 10% or 5% heat-inactivated calf serum (Colorado Serum, Denver) in a humidified atmosphere of 5% CO 2 ͞air.
Mutagenesis, Cloning, and Expression of the MET PRC Mutants. A recombinant PCR-based approach using the human MET cDNA as a template was applied to construct the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact. Association with Signal Transducers. Cells expressing wildtype or MET PRC mutants were lysed with EB buffer (100 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate), immunoprecipitation was performed with the indicated antibodies. After SDS͞PAGE, proteins were transferred to Hybond-enhanced chemiluminescence membranes (Amersham) by high-intensity wet blotting. Filters were probed with the appropriate antibodies and specific binding was detected by enhanced chemiluminescence system (Amersham). When indicated, the association experiments were performed in the presence of Metderived peptides (50 M) as described (29) .
Focus-Forming and Soft Agar Growth Assays. NIH 3T3 cells were transfected at a density of 1.5 ϫ 10 5 cells per 100-mm plate by the calcium phosphate method, using 40 g per plate carrier DNA (calf thymus high-molecular-weight DNA, Boehringer Mannheim). For detection of foci, cells were maintained in DMEM containing 5% calf serum (Colorado Serum, Denver), and foci were scored 3 weeks after transfection following fixation in 3% paraformaldehyde and Giemsa staining. For selection of stable transfectants, cells were maintained in DMEM containing 10% calf serum and 750 g͞ml G418. After selection, resistant clones were pooled and expanded. For analysis of colony formation in soft agar, different cell dilutions (10 5 - 10 6 ) in 4 ml of DMEM containing 10% calf serum and 0.5% Seaplaque agarose (FMC) were seeded in 6-mm plates containing a 1% agarose underlay. Cultures were fed every 4 days, and the formation of colonies was scored after 3 weeks.
Peptides, Electroporation, and Invasion Assays. For electroporation, adherent cells were cultured onto 3.2-cm 2 indium-tin oxide conductive glass surfaces and electroporated in situ with PBS containing the phosphorylated or nonphosphorylated peptides (100 M). The electric pulse was generated by the Epizap apparatus (Ask Science Products, Ontario, Canada), as described (30) . More than 90% of cells were permeabilized as tested by the uptake of Lucifer yellow, and viability was greater than 80%, as judged by trypan blue exclusion. For Matrigel (Becton Dickinson)invasion assays, cells were seeded on fibronectin-coated conductive slides and grown to confluence. After electroporation with the indicated peptides, the cell monolayer was wounded and covered with Matrigel containing laminin, collagen type IV, proteoglycans, and growth factors. Cells were cultured for 8-12 hr in serum-free medium. The invasive phenotype was evaluated by counting the cells that invaded the wounded area (Ϸ0.5 mm 2 ). Invasive growth in collagen was assessed in three-dimensional collagen gels (30) . Single cells were suspended (2,000 cells per ml) on ice in gelling solution containing 8 parts type I collagen (2 mg͞ml stock solution G collagen, Seromed, Milan), 1 part 10ϫ DMEM, and 1 part Hepes (0.5 M, pH 7.4). The cold mixture was placed into microtiter plate wells and allowed to polymerize for 15 min at 37°C before adding 0.1 ml of DMEM supplemented with 20% fetal calf serum. Cells were cultured for 5 days and examined under a phase-contrast microscope.
RESULTS AND DISCUSSION
It was recently shown that MET mutants, found in PRCs, transform fibroblasts in vitro and promote tumorigenesis in nude mice (12) . All PRC mutations are located within the receptor tyrosine kinase domain (Fig. 1 ). Molecular modeling indicated that some of the mutations (D1228N, D1228H, Y1230C, Y1230H, and M1250T) alter residues located in the activation loop (22) . The activation loop plays a key role in converting inactive receptor tyrosine kinases into their active form and has been implicated in autoinhibition of substrate binding (31) . We therefore analyzed the effects of the mutations on the catalytic properties of the MET kinase by measuring either phosphorylation of an exogenous substrate ( Fig. 2A) or phosphorylation of the receptor tail (Fig. 2B ) using a peptide mimicking the docking sites (Y 1349 VHVNATY 1356 VNV). Interestingly, the mutations affecting the activation loop are associated with the highest catalytic activity and with increased phosphorylation of the receptor tail. As expected (12), a correlation was found between the catalytic properties and the transforming ability, which was most marked for M1250T, the mutation occurring in RET in the MEN2B syndrome (2, 10). To assess whether the PRC mutations could alter the substrate specificity of MET, we measured the phosphorylation of peptides that are known to be optimal substrates for tyrosine kinases of either the receptor or the cytosolic type (14) . Minor changes in substrate specificity, compared with wild-type MET, were observed in the Y1230H, D1228H, and D1228N mutants. A more marked shift in substrate specificity was observed with the M1250T mutant, which phosphorylated more efficiently peptides that are optimal substrates for cytosolic tyrosine kinases such as Abl (Fig. 2C) . Thus, the substrate infidelity displayed by the RET receptor mutated in MEN2B is also observed in the corresponding MET PRC mutant. It should be noted however, that even the M1250T mutant phosphorylates the tail peptide with higher efficiency (3-fold) than any other peptide substrate (Fig. 2 B vs. C) . Altogether these experiments suggest that the transforming PRC mutations not only up-regulate the kinase activity, resulting in increased ability to phosphorylate the receptor tail, but in some cases may also alter the substrate specificity. We next assessed whether, in view of its altered substrate specificity, the M1250T mutant was able to phosphorylate cellular substrates that are normally phosphorylated by the Abl tyrosine kinase, among which are Crk and p130 CAS (32) . We found that in NIH 3T3 cells transfected with the M1250T mutant and other MET PRC mutants, the level of tyrosine phosphorylation of p130 CAS was slightly increased with respect to control or wild-type transfected cells, whereas the levels of Crk phosphorylation were unaffected (data not shown).
We next examined the effects of the PRC mutations on signal transduction. For this purpose, wild-type or PRCmutated MET receptors were stably expressed in NIH 3T3 cells (Fig. 3 A and B) . For each receptor mutant, the level of protein expression and of tyrosine phosphorylation was evaluated by immunoprecipitation experiments. The receptors harboring the Y1230C, Y1230H, D1228H, D1228N, and M1250T mutations were found to be tyrosine-phosphorylated in intact cells (Fig. 3A) . Densitometric analysis showed that some of the MET PRC mutants display an increased level of tyrosine phosphorylation with respect to wild-type MET. The increase varies from 2-to 3-fold for the M1131T, Y1230C, and Y1230H mutants to 5-to 7-fold for the V1220I, D1228H, D1228N, and M1250T mutants.
We next analyzed, by coimmunoprecipitation experiments, the effect of the PRC mutations on receptor coupling to signal transducers. We found that receptors harboring the Y1230H, D1228H, D1228N, and M1250T mutations were constitutively associated with signal transducers (Fig. 3B) . These include the multiadaptor protein Gab1 (Fig. 3B) , the Grb2͞SOS complex, and the p85 regulatory subunit of phosphatidylinositol 3-kinase (data not shown). Previous work has demonstrated that concomitant activation of these effectors is responsible for invasive growth (23, 33) . The ability of MET PRC mutants to associate in a constitutive fashion with signal transducers correlates directly with their transforming potential (Fig. 3B vs.  Fig. 4A ).
To identify the critical mechanism(s) responsible for transformation (namely, the altered properties of the kinase versus constitutive coupling to physiological signal transducers), we uncoupled tyrosine kinase alterations from signal transduction by converting the two docking tyrosines of MET PRC mutants into phenylalanines (Fig. 1 ). This Y 3 F conversion abrogated the association with signal transducers (Fig. 3B ) but did not affect constitutive activation and autophosphorylation of the mutants (Fig. 3A) . As previously shown (26) , the lack of phosphorylation of the tail residues Y 1349 -Y 1356 can be monitored by the faster electrophoretic mobility of the MET protein immunopurified from transfected COS cells (Fig. 3C) . Interestingly, PRC mutants unable to bind their physiological signal transducers were dramatically impaired in their transforming potential in spite of the constitutive activation of the kinase (Fig. 4A) . In addition, their ability to induce anchorageindependent growth (Fig. 4B) and to invade reconstituted basement membranes was also impaired (Fig. 5A ). Previous work with cells transformed by a rearranged form of MET (TPR-MET) showed a direct correlation between the behavior in these in vitro assays and the invasive-metastatic phenotype in vivo (23) .
These results indicate that constitutive coupling of signal transducers to the receptor tail is a key mechanism in MET PRCinduced neoplastic transformation and suggest the possibility of interfering with this process by exogenous molecules. To this end, we tested whether a peptide mimicking the MET docking site could displace signal transducers (e.g., Gab1) in vitro. The phosphorylated synthetic peptide Y p VNV, but not the unphosphorylated control FVNV, was found to be effective (Fig. 3D) . Similar results were obtained with p85 and Grb2 (data not shown). To disrupt the interaction between MET PRC and signal transducers in living cells, we synthesized derivatives of the same peptides, where the phosphate was replaced by a phosphonate group (resistant to phosphatases) and the N and C termini were modified to prevent proteolytic degradation (30) . The peptides were introduced by in situ electroporation in cells transformed by MET PRC mutants and the invasive phenotype evaluated in the above-mentioned in vitro assay. The tyrosinephosphorylated peptide, but not its phenylalanine counterpart, prevented invasion of the reconstituted basement membrane by cells transformed by the D1228H mutant (Fig. 5A) . The inhibition was as effective as the Y 3 F conversion in the receptor's docking site. The same phosphorylated peptide specifically inhibited sprouting and migration of cells transformed by the D1228H mutant into a three-dimensional network of collagen (Fig. 5B) . Similar inhibition in both assays was observed when other transforming MET PRC mutants were tested.
These experiments show that the transforming and invasive potential of MET PRC mutants relies on their constitutive coupling to downstream signal transducers. When this interaction is disrupted, the oncogenic properties are abrogated. Furthermore, these observations provide proof-of-concept for a signaling-based therapeutic strategy aimed at interfering with diseases associated with MET, or with tyrosine kinase receptors encoded by other oncogenes.
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